BMO Capital Markets Initiates Coverage on Avidity Biosciences (NASDAQ:RNA)
BMO Capital Markets assumed coverage on shares of Avidity Biosciences (NASDAQ:RNA – Free Report) in a research note issued to ...
Avidity Biosciences (NASDAQ:RNA) Now Covered by Analysts at Citigroup
Investment analysts at Citigroup began coverage on shares of Avidity Biosciences (NASDAQ:RNA – Get Free Report) in a research ...
Fintel on MSN1d
Citigroup Initiates Coverage of Avidity Biosciences (RNA) with Buy Recommendation
Fintel reports that on March 13, 2025, Citigroup initiated coverage of Avidity Biosciences (NasdaqGM:RNA) with a Buy ...
Avidity Biosciences initiated with a Buy at Citi
Citi initiated coverage of Avidity Biosciences (RNA) with a Buy rating and $70 price target Healthcare policy remains a key biopharma sector ...
Le Lézard2d
Avidity Biosciences Announces Upcoming Presentations at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
Aravindhan Veerapandiyan, MD, Associate Professor of Pediatrics, University of Arkansas for Medical Sciences and Arkansas Children's Hospital and EXPLORE44® trial investigator, will present topline ...
This S&P Global Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
B. Riley Securities analyst Yuan Zhi initiated coverage on Radiopharm Theranostics Limited RADX with a Buy rating and ...
Fintel on MSN3d
BMO Capital Initiates Coverage of Avidity Biosciences (RNA) with Outperform Recommendation
Fintel reports that on March 12, 2025, BMO Capital initiated coverage of Avidity Biosciences (NasdaqGM:RNA) with a Outperform ...
Avidity Biosciences initiated with an Outperform at BMO Capital
BMO Capital initiated coverage of Avidity Biosciences (RNA) with an Outperform rating and $72 price target Avidity’s pipeline includes ...